Home › Premarket Biotech Digest: Breast Cancer Therapies, Anavex's Milestone, Praluent EU Approval
 

Keywords :   


Premarket Biotech Digest: Breast Cancer Therapies, Anavex's Milestone, Praluent EU Approval

2015-09-29 16:11:27| Biotech - Topix.net

Targeted therapies in breast cancer are the latest developments in this area of therapeutics. Although these therapies sometimes cause serious side effects, for example, damage to heart muscles in some HER2 inhibitors, they offer a non-surgical option for treating breast cancer.

Tags: approval cancer breast digest

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
24.111000 15
24.11 nike soccer usa national team uniform
24.1160266
24.11 1
24.11
24.11GREATEST HITS ALTER EGO EGOIST
24.11(ALINCO)
24.11[]34
More »